Advertisement

Topics

Companies Related to "Role of Exercise in Diastolic Heart Failure" [Most Relevant Company Matches] - Page: 2 RSS

15:56 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Role of Exercise in Diastolic Heart Failure" found in our extensive corporate database of over 50,000 company records.

Showing "Role Exercise Diastolic Heart Failure" Companies 26–50 of 1,400+

Relevant

American Association of Heart Failure Nurses (AAHFN)


Ablative Solutions, Inc.

Ablative Solutions, Inc., based in Kalamazoo, Michigan, and San Jose, California, was founded in 2011 with a vision to address the unmet need of hypertension. Ablative Solutions’ approach targets the overactive sympathetic nervous system, which may play a role in hypertension, heart failure, kidney disease, metabolic syndrome and sleep apnea.1, 2 The ...

Angeion

Through rapid analysis of an individual's inhaled and exhaled breath, Angeion's advanced technologies provide physicians, health professionals, trainers and coaches with a non-invasive diagnostic window to view a person's overall cardiorespiratory health and fitness. The clinical importance ranges from prevention to early detection and effective management of a wide range of cardiopulmonary disea...


CircuLite

CircuLite® is transforming heart failure treatment with the development of minimally invasive devices for long-term partial circulatory support (PCS). By enabling a proactive and lower-risk treatment approach by supplementing a patient’s native pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart ...

Cardiome Pharma

Cardiome Pharma Corp is a drug development company focused on proprietary drugs to treat or prevent cardiac diseases. Cardiome's drug development efforts target the treatment of cardiac arrhythmia (irregular beating of the heart), through the use of atria-selective ion channel modulating drugs,and congestive heart failure (CHF), through the use of drugs known to improve oxygen use in the sick hear...

Intercure, Inc.

InterCure, a medical device company has developed and patented a technology platform for respiratory-based treatment of cardiovascular and pulmonary diseases. The Company has incorporated its "Interactive Respiratory-Pacing" technology platform into several product lines, the first two of which offer a new therapeutic class of non-drug treatments for two of the most widespread and costly disease s...

Pulmonary Hypertension Association

Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The function of the heart and lungs is severely compromised, manifested by a limited exercise capacity, and, ultimately, a reduced life expectancy. Approximately 100,000 people in Europe and the United S...

Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure(R), is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology ...

Reprieve Cardiovascular, Inc.

Reprieve Cardiovascular’s Guided Diuretic Therapy is designed to manage fluids during diuretic therapy for patients with Acute Decompensated Heart Failure (ADHF), and may relieve a number of symptoms related to this condition. The therapy has the potential to enable precise and predictable management of a patient’s fluid levels, guarding against ...

Cardurion Pharmaceuticals

"Cardurion is targeting key and well validated pathways to enhance heart function,” said Dr. Eric Olson, scientific advisory board chairman, Cardurion Pharmaceuticals. “Cardurion has a tremendous team with deep expertise in developing pioneering therapies, and I look forward to working alongside these leaders to advance treatments for heart failure ...

Vasogen

We are focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The recently completed international 2,400-patient ACCLAIM trial assessed the impact of our Celacade™ technology on reducing the risk of mortality and morbidity in patients with advanced heart failure. Full results for the ACCLAIM study ...

NanoCor Therapeutics, Inc.

NanoCor Therapeutics, Inc. ("NanoCor") is a biotechnology company founded to create the first viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure ("CHF"). The company was spun off from Asklepios BioPharmaceutical, Inc. in August 2005.CHF is the end product of a number of cardiovascular diseases that degrade the heart's ability to pump blood efficiently. The Ame...

Abiomed Incorporated

Abiomed (NASDAQ: ABMD) is a global technology leader focused on RECOVERING HEARTS AND SAVING LIVES. The Company's portfolio of heart support and recovery products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the catheterization lab to the surgical suite, together with interventional cardiologists and surgeons, Abiomed is dedicated to provi...

CVRx, Inc.

CVRx, Inc. is a private company and is headquartered in Minneapolis. The company has developed the Barostim neo for the treatment of high blood pressure and heart failure. For more information, visit www.cvrx.com.

Jewish Hospital and University of Louisville

Jewish Hospital, a part of KentuckyOne Health, is an internationally renowned high-tech tertiary referral center developing leading-edge advancements in hand and microsurgery, heart and lung care, home care, cancer care, rehab medicine, sports medicine, orthopaedics, neuroscience, occupational health, organ transplantation and outpatient and primary...

Miracor Medical Systems GmbH

Based in Vienna, Austria, privately held Miracor is commercializing a unique and potentially disruptive technology, PICSO®, for acute coronary syndrome (ACS), heart failure, and cardiac surgery patients. The Company’s objective is to establish PICSO® as the standard of care for heart attack patients, thereby improving their quality of life. The ...

Orangetheory Fitness

Orangetheory Fitness emphasizes the science of excess post-exercise oxygen consumption. The concept of heart-rate-monitored training is designed to keep heart rates in a target zone that stimulates metabolism and increases energy. Led by skilled instructors, participants use a variety of equipment including treadmills, rowing machines, SBT Suspension ...

CircuLite, Inc.

CircuLite is developing disruptive solutions to improve the treatment of advanced heart failure. The Company’s minimally invasive circulatory support systems are intended to work in conjunction with the heart to enhance clinical outcomes and improve quality of life for patients and their families. Synergy®, currently in a CE Mark clinical trial, fe...

HeartWare Inc.

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surg...

The Centre of Excellence for the Prevention of Organ Failure

The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) develops blood tests to diagnose, treat and manage heart, lung and kidney disease. The PROOF Centre is a cross-disciplinary engine of partners representing academia, health care, government, industry, patients and the public, to improve heart, lung and kidney health and reduce the ...

Epsilon Imaging, Inc.

Strain Imaging can provide repeatable assessment of regional heart mechanics and consistent global functional parameters (EF and global strain). This added information can reduce interpretation time on the visually demanding cases and increase confidence for experienced and novice readers. Quantification of tissue motion and contraction can also reduce var...

HeartWare International, Inc.

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surg...

Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies, intelligent devices and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The company works to prevent the worse...

VisCardia Inc

VisCardia based in Portland, OR is developing a novel implantable device therapy for treating heart failure, a condition that afflicts 10 million patients in the U.S. and Europe. To learn more about VisCardia, visit: http://www.viscardia.com

VisCardia Inc.

VisCardia, based in Portland, OR, is developing a novel implantable device therapy for treating heart failure, a condition that afflicts 10 million patients in the U.S. and Europe. To learn more about VisCardia, visit: http://www.viscardia.com.


More From BioPortfolio on "Role of Exercise in Diastolic Heart Failure"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks